103 related articles for article (PubMed ID: 6505385)
1. Central serotonin antagonist activity of ketanserin.
Fuller RW; Snoddy HD
Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):151-4. PubMed ID: 6505385
[TBL] [Abstract][Full Text] [Related]
2. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
[TBL] [Abstract][Full Text] [Related]
3. Flumezapine, an antagonist of central dopamine and serotonin receptors.
Fuller RW; Mason NR
Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):23-34. PubMed ID: 2879325
[TBL] [Abstract][Full Text] [Related]
4. Adaptation of brain 5HT2 receptors after mianserin treatment: receptor sensitivity, not receptor binding, more accurately correlates with behavior.
Smith RL; Barrett RJ; Sanders-Bush E
J Pharmacol Exp Ther; 1990 Aug; 254(2):484-8. PubMed ID: 2166792
[TBL] [Abstract][Full Text] [Related]
5. Serotonin receptor subtypes involved in the elevation of serum corticosterone concentration in rats by direct- and indirect-acting serotonin agonists.
Fuller RW; Snoddy HD
Neuroendocrinology; 1990 Aug; 52(2):206-11. PubMed ID: 2148812
[TBL] [Abstract][Full Text] [Related]
6. The specificity of ketanserin in the inhibition of serotonin-induced steroidogenesis in the rat adrenal zona glomerulosa.
Williams BC; Shaikh S; Edwards CR
J Hypertens Suppl; 1984 Dec; 2(3):S559-61. PubMed ID: 6100754
[TBL] [Abstract][Full Text] [Related]
7. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
Lucki I; Nobler MS; Frazer A
J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
Smith RL; Barrett RJ; Sanders-Bush E
J Pharmacol Exp Ther; 1995 Nov; 275(2):1050-7. PubMed ID: 7473132
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of a peripheral vascular but not an apparently central serotonergic response by xylamidine and BW 501C67.
Fuller RW; Kurz KD; Mason NR; Cohen ML
Eur J Pharmacol; 1986 Jun; 125(1):71-7. PubMed ID: 3732393
[TBL] [Abstract][Full Text] [Related]
10. Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.
Hemrick-Luecke SK; Fuller RW
Eur J Pharmacol; 1996 Sep; 311(2-3):207-11. PubMed ID: 8891601
[TBL] [Abstract][Full Text] [Related]
11. Three distinct subtypes of serotonergic receptors mediate the triphasic blood pressure response to serotonin in rats.
Kalkman HO; Engel G; Hoyer D
J Hypertens Suppl; 1984 Dec; 2(3):S143-5. PubMed ID: 6599662
[TBL] [Abstract][Full Text] [Related]
12. The effects of metergoline and other serotonin receptor antagonists on serum corticosterone in rats.
Fuller RW; Snoddy HD
Endocrinology; 1979 Oct; 105(4):923-8. PubMed ID: 477605
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate.
Fuller RW; Snoddy HD
Res Commun Chem Pathol Pharmacol; 1992 Jul; 77(1):87-93. PubMed ID: 1359615
[TBL] [Abstract][Full Text] [Related]
14. Quipazine reduces food intake in the rat by activation of 5-HT2-receptors.
Hewson G; Leighton GE; Hill RG; Hughes J
Br J Pharmacol; 1988 Oct; 95(2):598-604. PubMed ID: 2906561
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological evidence for a role of brain serotonin in the maintenance of plasma renin activity in unanesthetized rats.
Van de Kar LD; Wilkinson CW; Ganong WF
J Pharmacol Exp Ther; 1981 Oct; 219(1):85-90. PubMed ID: 6457138
[TBL] [Abstract][Full Text] [Related]
16. pH-dependent modulation of agonist interactions with [3H]-ketanserin-labelled S2 serotonin receptors.
Battaglia G; Shannon M; Borgundvaag B; Titeler M
Life Sci; 1983 Nov; 33(20):2011-6. PubMed ID: 6645787
[TBL] [Abstract][Full Text] [Related]
17. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
Friedman RL; Barrett RJ; Sanders-Bush E
J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
[TBL] [Abstract][Full Text] [Related]
18. On the mechanism of action of ketanserin, a selective antagonist of the S2 receptors with antihypertensive activity.
Rión R; Mena MA; Hong E
Proc West Pharmacol Soc; 1983; 26():373-5. PubMed ID: 6889366
[No Abstract] [Full Text] [Related]
19. Serotonin type 2 antagonists inhibit lordosis behavior in the female rat: reversal with quipazine.
Mendelson SD; Gorzalka BB
Life Sci; 1986 Jan; 38(1):33-9. PubMed ID: 2934598
[TBL] [Abstract][Full Text] [Related]
20. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats.
Cohen ML; Fuller RW; Kurz KD
Hypertension; 1983; 5(5):676-81. PubMed ID: 6311738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
